Noncoding Rnas as Novel Biomarkers in Pancreatic Cancer: what do we Know? | Zendy

Maria C. Previdi | Zendy; Pietro Carotenuto | Zendy; Domenico Zito | Zendy; Rosantony Pandolfo | Zendy; Chiara Braconi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Noncoding Rnas as Novel Biomarkers in Pancreatic Cancer: what do we Know?

Author(s) -

Maria C. Previdi,

Pietro Carotenuto,

Domenico Zito,

Rosantony Pandolfo,

Chiara Braconi

Publication year - 2016

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2016-0253

Subject(s) - pancreatic cancer , medicine , cancer , clinical significance , biomarker , carcinogenesis , bioinformatics , oncology , biology , biochemistry

Pancreatic cancer is an aggressive cancer of the digestive system, which is becoming a serious health problem worldwide. Overall survival for patients with pancreatic cancer is poor, mainly due to a lack of biomarkers to enable early diagnosis and a lack of prognostic markers that can inform decision-making, facilitating personalized treatment and an optimal clinical outcome. ncRNAs play an important role in pancreatic carcinogenesis. Here we review the literature on the role of ncRNAs as biomarkers in pancreatic cancer. We focus on the significance of ncRNAs as markers for early diagnosis, as prognostic biomarkers able to inform clinical management and as targets for novel therapeutics for patients with pancreatic cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research